The disappointing results in the treatment of primary myelofibrosis (PM) with interferon, reviewed by Kiladjian et al., 1 with no objective responses in 84 PM patients, have prompted us to submit this letter regarding our success of using low-dose interferon in treating early-stage PM. In this study, we sought to avoid the progression of disease in patients who had early-stage disease. Those treated with interferon were good-risk patients, with relatively good blood cell counts and minimal to moderate bone-marrow fibrosis. We report here that early treatment in this good-risk group showed an improvement in bone-marrow fibrosis and in the control of splenomegaly. The use of interferon is based on its effects on megakaryopoiesis, which include decreasing megakaryocyte density and size, 2 inhibiting thrombopoietin-induced signaling, 3 suppressing the expression of transcription factors 4 and reducing levels of platelet-derived growth factor, 5 all of which play a major role in the pathogenesis of myelofibrosis. 1 The diagnosis of PM was established clinically, hematologically and by bone-marrow trephine biopsy, consistent with published criteria. [4] [5] [6] Pretreatment evaluation included history, physical examination, complete blood cell count and differential CD34 count, BCR-ABL and JAK2 V617F allele burden determinations, serum chemistries and thyroid function tests. Spleen size was categorized as not enlarged, slightly enlarged (1-3 cm), moderately (4-9 cm) or markedly enlarged (49 cm), as palpated below the costal margin in the mid-clavicular line. Exclusion criteria included marrow findings as below, and the usual contraindications to recombinant interferon alpha-2b (rIFNa). 7 The bone-marrow biopsy specimens, routinely processed, were stained with hematoxylin-eosin and giemsa, and for reticulin and collagen, quantified by the method of Manoharan, et al. 6 Excluded patients showed advanced fibro-osteosclerosis, grade 3 or 4 reticulin deposition, coarse bundles of collagen fibers 6 and no residual hematopoiesis. Patients considered for study required hematopoietic foci occupying at least 30% of the marrow biopsy, and no more than grade 2 reticulin or collagen fibrosis. Before treatment, nine patients had a Lille 8 risk score of 0, three had a score of 1 and one patient had a score of 2. None of the patients required transfusions. After treatment, 11 patients had a Lille risk score of 0 and two had a score of 1 (Table 1) . We began treatment with rIFNa-2b at 500 000-1 000 000 units, subcutaneously, thrice weekly, increasing the dose gradually to 2-3 million units thrice a week, as tolerated and if necessary, in order to reduce the spleen size when present. Spleen size was used as a clinical marker of drug effect in patients with splenomegaly. Toxicity was evaluated using the International Common Toxicity Criteria, version 3.0 (http://ctep.cancer.gov/reporting/ctc.html). Approval for this retrospective analysis was obtained from the Weill Cornell Medical College Institutional Review Board.
Of the 59 patients with PM evaluated for rIFNa-2b therapy, 46 were excluded because of a markedly fibrotic or osteosclerotic marrow or because of nonelection of rIFNa-2b therapy. Of the remaining 13 patients, who met our admission criteria and who elected therapy, 11 were women and 2 were men with mean and median ages of 56 and 57 years, respectively (range 36-75 years). The median duration of disease before treatment was 1 year (range 0-18 years). Before interferon, the median white blood cell count for the group of patients was 7.10k/ml (range 2.0-41.4k/ml), the median hematocrit level was 35.5% (range 25.2-39.3%), the median hemoglobin level was 11.7 g per 100 ml (range 8.7-13.4 g per 100 ml) and the median platelet count was 268 000/ml (range 98 000-661 000/ml) ( Table 1) . Two of the 13 patients had no splenomegaly at onset, and remained so during treatment. Initially, the spleen was slightly enlarged in four, and moderately or markedly enlarged in seven. Eleven patients had a change in spleen size after rIFNa-2b (Figure 1 ). The spleen became non-palpable in all four patients who initially had slight splenomegaly, but in only one of two patients with moderate splenomegaly and in three of five with marked splenomegaly. Three patients with moderate or marked splenomegaly had only a transient response to rIFNa-2b, which lasted only 1 year. Thus, patients with slight splenomegaly responded best to rIFNa-2b therapy. The median spleen sizes in centimeters below the left costal margin were 7.0 cm (range 0.0-24.0 cm) before treatment, and 0 cm (range 0.0-20.0 cm) at last follow-up (Table 1) . Our results are thus in sharp contrast with those reported in the literature by Kiladjian et al.
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Bone marrow follow-up studies were possible in nine of the 13 patients, and were carried out a median of 2.3 years after the start of the rIFNa-2b therapy (range 1.2-5.0 years). The median duration of interferon treatment was 3.0 years (range 0.17-13.4 years). Reduction of abnormal marrow morphology occurred in five of nine patients. Reticulin and collagen fibrosis diminished in three of five patients (Manoharan score 2-1 6 ), and was Letters to the Editor virtually absent in two. A trend toward normalization of megakaryocytic atypia and increased normal hematopoiesis was observed (Figures 2 and 3) . Of these five patients, the spleen was reduced in four. Thus, a reduction in spleen size (more likely with smaller-sized spleens) correlated usually, but not always, with an improvement in marrow morphology.
Of the 13 patients, seven were JAK2 V617F positive. The median allele burden was 33.2%. Four patients, all responders, had follow-up JAK2 analyses. Three of these four patients showed no reduction in allele burden. The fourth patient had a sequential decrease in allele burden from 45.6 to 11.2% over 3 years. However, this patient had no splenomegaly at the onset of therapy or thereafter, and no change in abnormal marrow morphology. Therefore, spleen and marrow response did not always correlate with a change in allele burden, nor did abnormal cytogenetic studies found in three patients, reflecting the complexity of the disease. 9 In contrast to reports cited by Kiladjian et al.,
1 rIFNa-2b was well tolerated at these doses. Grade 1 toxicity occurred in six of the 13 patients, including mild depression, dry skin, cough, myalgia and asthenia, which did not require dose reduction. One patient developed hyperthyroidism, and rIFNa-2b was discontinued. Nine patients experienced mild cytopenias during treatment on doses of rIFNa-2b ranging from 1 000 000-2 000 000 units thrice weekly, which in general were dose related. One of the 13 had a grade 1 decrease in white blood cell count, one had a grade 3 decrease in hemoglobin level, one had a grade 2 decrease in platelet count, but with disappearance of splenomegaly (17 to 0 cm), and seven had as much as a 15% decrease in hematocrit value. In these seven patients, the dose of interferon was temporarily interrupted or reduced, as required.
One patient had a significant reduction in spleen size (12 to 2 cm), and a reduction in the hematocrit level (38.8-30.1%) and platelet count (207 to 125k/ml). These effects were attributed to interferon, and, at the time of writing this letter, her dose has been reduced by 50%. No patient had permanent discontinuation because of hematological toxicity. After treatment with interferon, the median white blood cell count was 6.0k/ml (range 3.4-26.8k/ml), the median hematocrit level was 32.8% (range 23.3-41.7%), the median hemoglobin level was 11.2 g per 100 ml (range 7.8-14.1 g per 100 ml) and the median platelet count was 299 000/ml (range 63 000-865 000/ml) ( Table 1) .
Progression-free survival, as measured by a reduction in the spleen size, was 75.2% at 2 years (confidence interval 40.7, 91.4%). Three patients with marked splenomegaly, without significant response lasting more than 1 year, are considered treatment failures, whereas 10 patients with no, slight or moderate splenomegaly remain on treatment.
In summary, treating patients with small doses of rIFNa-2b in the early stage of disease, over an extended period, when the marrow was not completely fibrotic or osteosclerotic, resulted in a regression of splenomegaly, an improvement of marrow architecture in five patients and a significant decrease in reticulin and collagen fibrosis in three, to date. In view of the lack of success in treating PM, cited by Kiladjian et al., we hope that this single-arm phase II pilot study, with its appreciated limitations but noteworthy findings, will stimulate a more systematic evaluation. We call attention to the potential usefulness and uniqueness of this type of medical therapy, which seems to control splenomegaly, affect progression-free survival and, most importantly, alter bone-marrow morphology. 
